Neurological Sciences最新文献

{"title":"Sex and age differences in sleep disorders: insights from a diverse cohort referred to a sleep center.","authors":"Ilde Pieroni, Gianluigi Cerroni, Lucia Velluto, Sandro Sorbi, Biancamaria Guarnieri","doi":"10.1007/s10072-025-08133-7","DOIUrl":"https://doi.org/10.1007/s10072-025-08133-7","url":null,"abstract":"<p><p>Sleep health is influenced by sex, gender, and age, with various sleep disorders exhibiting different prevalence rates and clinical presentations among different demographic groups. This retrospective study investigated sex and age differences in a diverse cohort of patients referred to an Italian sleep center for comprehensive sleep evaluations over a four-year period. Medical records of 909 consecutive patients who underwent overnight video-polysomnography between January 2014 and December 2017 were reviewed. Socio-demographic, anthropometric, clinical, and sleep-related data were extracted and compared between male and female patients across different age groups. Our analyses revealed disparities in the access to sleep evaluations, socio-demographic characteristics and lifestyle habits between males and females across age groups. Comorbidities varied, with cardiovascular diseases more prevalent in males, while thyroid disorders, rheumatologic conditions, and psychiatric disorders more common in females. Female patients also reported higher rates of psychotropic medications use at admission. Males had higher rates of obstructive sleep apnea, while females, particularly in middle and older age groups, exhibited more insomnia disorder and restless legs syndrome. Notably, the co-occurrence of multiple sleep disorders was observed, particularly among older individuals and female patients. Our findings emphasize the importance of considering sex and age differences in diagnosing and managing sleep disorders. Tailored approaches are necessary to optimize sleep health and overall well-being, particularly in aging populations, where sleep disturbances often coexist with other chronic conditions. Further research is warranted to elucidate the complex interplay between sex, gender, and age to promote sleep equity and improve patient care.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of gait recovery with intramuscular coherence of the Vastus medialis muscle during assisted gait in subacute stroke.","authors":"Naruhito Hasui, Naomichi Mizuta, Ayaka Matsunaga, Yasutaka Higa, Masahiro Sato, Tomoki Nakatani, Junji Taguchi, Shu Morioka","doi":"10.1007/s10072-025-08138-2","DOIUrl":"https://doi.org/10.1007/s10072-025-08138-2","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to investigate the effect of descending neural drive during assisted gait training on gait recovery in non-ambulatory stroke patients and the effect of 1-month gait training on the descending neural drive.</p><p><strong>Methods: </strong>Twenty stroke patients unable to walk independently were included in this longitudinal study. Intermuscular coherence analysis (beta band; 15-30 Hz) was performed on electromyography signals recorded from the proximal and distal segments of the vastus medialis (VM) and lateral hamstring (LH) on the paretic side (i.e., VM-VM, VM-LH, and LH-LH coherence) during assisted gait used knee-ankle foot orthosis. Lower limb flexion and extension angles and step count during training were also assessed. Gait recovery was assessed by the number of days required to achieve functional ambulation category (FAC) 3 (supervised gait) since stroke onset. The participants were then classified into the FAC 3-achieved and FAC 3-not achieved groups.</p><p><strong>Results: </strong>Days to achieve FAC 3 was significantly associated with VM-VM coherence in the beta band (ρ = -0.648, p = 0.003). VM-VM coherence in the beta band during assisted gait significantly increased in the FAC 3-achieved group than in the FAC 3-not achieved group. In contrast, VM-LH and LH-LH coherence were not significantly associated with the days to achieve FAC3 and were not significantly increased by training.</p><p><strong>Conclusion: </strong>Stroke survivors who were unable to walk independently but had reacquired supervised gait exhibited high VM-VM coherence, which increased with gait training. This finding indicates the presence of residual descending neural drive related to weight acceptance.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroradiological insights into primary progressive apraxia of speech: a case report.","authors":"Nilanjana Patra, Sneha Rozelena Anthony, Mona Tiwari, Julián Benito-León, Durjoy Lahiri","doi":"10.1007/s10072-025-08136-4","DOIUrl":"https://doi.org/10.1007/s10072-025-08136-4","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty and hospital outcomes among patients with neurological disorders.","authors":"Marco Toccaceli Blasi, Fabrizio Raffaele, Daniele Belvisi, Simona Buscarnera, Giuseppe Bruno, Giovanni Fabbrini, Marco Canevelli","doi":"10.1007/s10072-025-08144-4","DOIUrl":"https://doi.org/10.1007/s10072-025-08144-4","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with neurological disorders, particularly those who are chronologically and biologically older, may display highly varied clinical courses and trajectories. The present study explored the association between frailty and hospital outcomes among patients with acute neurological presentations admitted to an Italian university hospital.</p><p><strong>Materials and methods: </strong>A cross-sectional study considered all patients consecutively admitted to the Neurology Unit of the Policlinico Umberto I University Hospital of Rome (Italy). A 40-item Frailty Index (FI) was retrospectively developed based on the clinical information collected in the Emergency Department (ED). Data on hospitalization outcomes were prospectively collected during the patient's stay at the Neurology Unit. Linear and logistic regression models were conducted to test the association between FI and hospital outcomes.</p><p><strong>Results: </strong>Overall, 185 participants (women 50.3%; mean age 68.6, SD 18.6 years) were included. FI scores ranged between 0 and 0.43, with a median value of 0.15 [IQR 0.10], and were positively correlated with age (Spearman's rho 0.55, p < 0.001). In a linear regression model adjusted by age, sex, and diagnosis, FI was significantly associated with the number of days spent in the Neurology Unit (B 2.18, 95%CI 0.25-4.11, per 0.1 increase; p = 0.03). In bivariate logistic regression models adjusted by age, sex, and diagnosis, increasing FI scores were significantly associated with a lower likelihood of being discharged at home (OR 0.37, 95%CI 0.20-0.63, per 0.1 increase; p < 0.001), with higher odds of nosocomial infections (OR 1.67, 95%CI 1.05-2.73 per 0.1 increase; p = 0.03), and prescription of antibiotics (OR 1.77, 95%CI 1.11-2.92, per 0.1 increase; p = 0.02).</p><p><strong>Conclusion: </strong>Frailty is adversely associated with hospital outcomes in patients with acute neurological disorders. Assessing frailty could improve patient stratification, prognostication, and care planning, with a relevant impact on healthcare resources.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality patterns in patients with type 2 diabetes mellitus and late-onset Alzheimer's disease in the United States: a retrospective analysis from 1999 to 2020.","authors":"Ahmed Raza, Eeshal Fatima, Abu Huraira Bin Gulzar, Mirza Ammar Arshad, Zain Ali Nadeem, Rahman Tanveer, Syed Hashim Ali Inam, Paul Ferguson","doi":"10.1007/s10072-025-08152-4","DOIUrl":"https://doi.org/10.1007/s10072-025-08152-4","url":null,"abstract":"<p><strong>Background: </strong>Late-onset AD refers to the occurrence of AD after the age of 65. It is the primary cause of late-onset dementia. Studies indicate that persons diagnosed with diabetes are more susceptible to late-onset AD. Diabetes manifests as insulin resistance, which can have significant effects on cognitive function and contribute to the development of AD.</p><p><strong>Methods: </strong>The CDC WONDER database was used to determine the crude death rates (CR) and age-adjusted mortality rates (AAMRs) per 100,000 individuals, 65 years and above. Joinpoint Regression Program was used to examine the changes in AAMR in the form of annual percent change (APC) and average annual percent change (AAPC).</p><p><strong>Results: </strong>From 1999 to 2020, late-onset AD and diabetes were associated with 185,059 deaths in the older US population, demonstrating an increasing trend (AAPC = 2.87). Females (20.38) had higher AAMR than males (19.62). Non-Hispanic (NH) African Americans experienced the highest AAMR (28.01), while non-Hispanic Asians experienced the lowest (16.09). AAMRs varied by region (West: 23.53, Midwest: 21.51, South: 21.0, Northeast: 13.50). States with the highest AAMR percent change were Nebraska and Louisiana; those with the lowest were Montana and New Hampshire. Most deaths occurred at hospice/nursing facilities (57.96%). Non-metropolitan areas showed a higher mortality burden (25.05) than metropolitan areas (19.02).</p><p><strong>Conclusions: </strong>There was an increasing mortality trend for late-onset AD among the population with diabetes in the US, with high mortality in females, NH African Americans, and the Western region.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early and active treatment with fingolimod for pediatric onset multiple sclerosis: the experience of an Italian pediatric center over the past 3 years.","authors":"Carlotta Canavese, Marta Borgogno, Gloria Gallo, Martina Rosa-Brusin, Alessia Teneggi, Aba Tocchet, Daniele Marcotulli, Giovanni Morana","doi":"10.1007/s10072-025-08139-1","DOIUrl":"https://doi.org/10.1007/s10072-025-08139-1","url":null,"abstract":"<p><strong>Aim: </strong>Describing the experience with early and high efficacy disease modifying treatment with fingolimod of a single Pediatric Multiple Sclerosis Center.</p><p><strong>Method: </strong>We analyzed all pediatric multiple sclerosis (POMS) patients treated with fingolimod between May 2021 and April 2024. The study assessed the efficacy of fingolimod treatment defined as the absence of clinical relapses, disability progression, and new/enlarging or enhancing lesions on MRI. Cognitive profile has also been assessed at symptoms' onset and after one year of treatment.</p><p><strong>Results: </strong>We included 6 patients (50% males) with average age at symptoms onset of 12.4 years and of 12.7 years at the diagnosis. Treatment with fingolimod was started on average 2.0 months (SD 1.7) after the diagnosis. The average treatment duration was 22.9 (SD 8.2) months and the average follow-up length 26.1 months (SD 8.9). None of the patients had clinical relapses during fingolimod treatment. Two patients showed new asymptomatic neuroradiological lesions after 18 months of treatment. All patients had normal cognitive profiles at first evaluation; four of them were tested after one year of treatment showing stable data.</p><p><strong>Interpretation: </strong>Fingolimod offers better compliance and significantly improves patients' quality of life compared to injection therapies especially in pediatric population, reducing injection associated anxiety and risk of discontinuation. It appears to be safe and well tolerated and may be used as first line treatment in the highly active and aggressive disease course of pediatric onset multiple sclerosis.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review.","authors":"Martina Gnazzo, Giulia Pisanò, Benedetta Piccolo, Emanuela Claudia Turco, Susanna Esposito, Maria Carmela Pera","doi":"10.1007/s10072-025-08155-1","DOIUrl":"https://doi.org/10.1007/s10072-025-08155-1","url":null,"abstract":"<p><p>Spinal muscular atrophy (SMA) frequently causes scoliosis (up to 90% of cases), due to weakened axial muscles impacting motor and respiratory function. While new SMA treatments improve motor function, their effect on scoliosis progression is unclear. This scoping review (2016-October 2024) analyzed literature from Pubmed, MEDLINE, EMBASE, and Scopus, focusing on studies of SMA, scoliosis, and treatment approaches. The aim of this work was to describe the clinical features and the possible therapeutic approaches of scoliosis in the \"new population\" of pharmacologically treated SMA patients. We included all types of SMA as well as all the approved disease modifying therapies (DMTs). The review found significant variability in scoliosis presentation and surgical intervention among different types of treated SMA patients. Early pharmacological treatment may slow scoliosis progression, particularly in Type II SMA. Interestingly, Type I SMA patients, who typically don't develop scoliosis due to severe hypotonia, showed an increased scoliosis onset. Larger studies are needed to fully evaluate the impact of different treatments on scoliosis progression in SMA, especially in Type I SMA patients, to establish updated standards of care.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mobility scale for acute stroke patients (MSAS): construct validity and reliability of the Italian scale.","authors":"Serena Di Tondo, Mariele Colucci, Laura Abbruzzese, Giovanni Galeoto, Marco Tofani, Pierluigi Zoccolotti, Mauro Mancuso","doi":"10.1007/s10072-024-07890-1","DOIUrl":"10.1007/s10072-024-07890-1","url":null,"abstract":"<p><strong>Background: </strong>The Mobility Scale for Acute Stroke Patients (MSAS) was developed to discriminate between the lower levels of mobility in acute stroke patients in the first two weeks post-onset.</p><p><strong>Objective: </strong>The present study aims to develop and validate an Italian version of the MSAS.</p><p><strong>Methods: </strong>The English version of the MSAS was translated into Italian according to international guidelines. We recruited 58 patients admitted to a rehabilitation facility within 14 days of the stroke onset and administered the MSAS to test the internal consistency, concurrent validity, reliability, and responsiveness of the scale.</p><p><strong>Results: </strong>As for internal consistency, Cronbach's alpha showed values equal to 0.96, and the alpha deleted analysis indicated that all the items have reason to exist. Concurrent validity showed statistically significant data for all sub-scales. The Italian version of the MSAS showed significant and high inter-rater reliabilities (all ICCs ≥ 0.75). The MSAS also showed excellent test-retest reliabilities (all ICCs ≥ 0.90). The reactivity of the scale, evaluated through the Student's t-test for paired samples on a sub-sample of 32 patients, showed statistically significant improvements over time for all items and the total scale.</p><p><strong>Conclusions: </strong>The results show that the scale is stable and reliable both in the evaluation after 24 h and between different operators. High internal consistency and a strong concurrent validity were found. The scale also proved able to detect the improvement obtained by patients following the rehabilitation treatments.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"1687-1694"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional and national temporal trends in Parkinson's disease incidence, disability-adjusted life year rates in middle-aged and older adults: a cross-national inequality analysis and Bayesian age-period-cohort analysis based on the global burden of disease 2021.","authors":"Jian Zhang, Yue Fan, Hao Liang, Yong Zhang","doi":"10.1007/s10072-024-07941-7","DOIUrl":"10.1007/s10072-024-07941-7","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) ranks as the second most prevalent neurodegenerative disorder; however, its epidemiological characteristics among middle-aged and older adults at global, regional, and national levels remain inadequately documented.</p><p><strong>Methods: </strong>This study assessed temporal trends in PD among middle-aged and older adults by extracting incidence rates, disability-adjusted life year (DALY) rates, and corresponding age-specific rates (ASRs) from the Global Burden of Disease (GBD) database spanning 1990 to 2021. Estimated annual percentage change (EAPC) was employed to analyze trends over the past 30 years. The slope index of inequality (SII) and concentration index (CI) were utilized to evaluate disparities in the burden of PD across various countries. Additionally, Bayesian age-period-cohort (BAPC) modeling was applied to project DALY figures for the next 15 years.</p><p><strong>Results: </strong>In 2021, the global incidence and DALY rates for middle-aged and older adults with PD stood at 79.68 and 477.50 cases per 100,000 population, respectively. Both incidence and DALY rates have exhibited an upward trajectory over the past 32 years, with EAPCs of 1.2 (95% UI: 1.1-1.3) and 0.6 (95% UI: 0.5-0.7), respectively. Among the five sociodemographic index (SDI) regions, the high-middle SDI region reported the highest incidence and DALY rates for PD in 2021, at 93.93 and 512.29 cases per 100,000 population, respectively. A positive correlation was observed between the SDI and age-specific incidence rate (ASIR) as well as age-specific DALY rate (ASDR). Disparities in the burden of PD among middle-aged and older adults, associated with SDI, are on the rise and are primarily concentrated in high SDI countries. It is projected that the global incidence and DALY rates for middle-aged and older adults with PD will experience significant increases over the next 15 years.</p><p><strong>Conclusions: </strong>The global burden of PD among middle-aged and older adults has markedly escalated over the past 32 years, particularly in high-middle SDI regions. These findings underscore the necessity for the development of effective interventions and public health policies, contributing to the attainment of the sustainable development goals established by the World Health Organization (WHO).</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"1647-1660"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmatic variability of direct oral anticoagulants in people with atrial fibrillation and previous gastric surgery: a pilot case series.","authors":"Michele Romoli, Maria Vitiello, Enrico Maria Lotti, Giuseppe D'Antuono, Arianna Berardo, Claudia Faini, Valentina Tudisco, Vincenzo Mastrangelo, Marco Longoni","doi":"10.1007/s10072-024-07937-3","DOIUrl":"10.1007/s10072-024-07937-3","url":null,"abstract":"<p><strong>Background: </strong>Data on cardioembolic prevention with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) patients with previous gastric surgery are lacking. We report inter- and intra-individual differences in DOAC concentration in people with gastric surgery, to identify potential treatment options.</p><p><strong>Methods: </strong>Patients with previous gastric surgery receiving DOAC for AF as stroke secondary prevention, and undergoing peak-trough DOAC plasmatic testing were selected from the regional EDDIE-AF registry. DOAC levels were tested at least 75-102 h after DOAC initiation with Siemens Innovance® assays.</p><p><strong>Results: </strong>Eight patients with previous gastric surgery were included (mean age 75 years, 50% women). Overall, only 20/36 tests were within range (55.5%; apixaban 75.0%; dabigatran 0%; edoxaban 64.3%; rivaroxaban 33.3%). Rivaroxaban and dabigatran failed to reach therapeutic peak-trough concentrations. Apixaban and edoxaban reached therapeutic levels in 4/6 and 3/7 cases respectively, with marginal out-of-target concentrations in all remaining cases.</p><p><strong>Conclusions: </strong>Our data support a consistent variability in DOAC absorption after gastric surgery, suggesting that implementation of DOAC plasmatic testing may help in ensuring therapeutic levels are met whenever DOACs are preferred over warfarin.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"1715-1719"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}